Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Leukemia, Myeloid, Acute 24Myelodysplastic Syndromes 5Leukemia, Biphenotypic, Acute 5Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Carcinoma, Hepatocellular 2Blast Crisis 2Sarcoma, Myeloid 1Recurrence 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Bevacizumab 47lenvatinib 36atezolizumab 36durvalumab 28tremelimumab 23sintilimab 19Nivolumab 18pembrolizumab 14Radiosurgery 13tislelizumab 11Specimen Handling 10Ipilimumab 10camrelizumab 8apatinib 8Oxaliplatin 8Immune Checkpoint Inhibitors 8Fluorouracil 8Cyclophosphamide 8Blood Specimen Collection 8regorafenib 7cabozantinib 7fludarabine 6Sorafenib 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Leucovorin 6donafenib 5Surgical Procedures, Operative 5Injections 5Immunoglobulin G 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Hepatocellular × Idarubicin × Clear all
NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡